WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Conditions

• Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex

ALL

Age

40 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• MTX-463 — BIOLOGICAL
  MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
• Placebo — OTHER
  Placebo

Study Details

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Key Dates

Start date

May 5, 2025

Status verified

May 2025

Primary completion

Aug 31, 2027

Completion

Aug 31, 2027

Study Design

Enrollment

164 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: MTX-463
  MTX-463
• Placebo Comparator: Placebo
  Placebo

Primary Outcome Measure

To assess the effect of MTX-463 on the change from Baseline in forced vital capacity (FVC) [ Time Frame: 24 Weeks ]

Central Contacts

• Jeffrey Bornstein, MD
  (617) 936-0960
  [email protected]
• Katherine Palu
  (617) 936-0960

Locations (26)

Find similar trials in Birmingham, AL

Related Studies

• Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• A Study of the Natural Progression of Interstitial Lung Disease (ILD)
  Recruiting · University of Chicago · Chicago, Illinois
• Mechanisms of Familial Pulmonary Fibrosis
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
  PHASE1/PHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania